Search clinical trials for: carboplatin

Total 3002 results

National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell... and other conditions

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer Neck
AbbVie

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Small Cell Lung Cancer

United States, Israel, Japan
Genmab
BioNTech SE

Recruiting

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Malignant Solid Tumor

Japan
Peter MacCallum Cancer Centre, Australia

Recruiting

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA)

Metastatic Triple Negative Breast Cancer

Australia
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Squamous Cell Carcinoma of Head and Neck

Canada, United States, Argentina, Australia, Brazil
Apexigen America, Inc.

Completed

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Esophageal Cancer | GastroEsophageal Cancer

United States
UNC Lineberger Comprehensive Cancer Center
AstraZeneca; Celgene

Active, not recruiting

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Carcinoma, Squamous Cell | Esophageal Cancer | Oral Cancer | Oropharynx Cancer | Larynx Cancer | Lip Cancer

United States
University of Chicago

Completed

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma

United States
National Cancer Institute, Naples
Mario Negri Institute for Pharmacological Research

Active, not recruiting

Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab (MITO16/MANGO-2)

Ovarian Cancer

Italy
Washington University School of Medicine
Aravive, Inc.

Withdrawn

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma
M.D. Anderson Cancer Center

Completed

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Prostate Cancer

United States
Bristol-Myers Squibb

Completed

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Lung Cancer - Non Small Cell Squamous

Belgium, Brazil, China, Germany, Hong Kong, Japan, Korea, Republic of, Taiwan, Thailand, United States, Spain, Australia, Italy, Netherlands, United Kingdom, Denmark, France, Argentina, Austria, Canada, Chile, Colombia, Czechia, Hungary, Irela... and more
Incyte Corporation
Bristol-Myers Squibb

Withdrawn

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Head and Neck Cancer
University of Florida

Terminated

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharynx Carcinoma

United States
Tanta University

Completed

Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia

Beta Thalassemia Major

Egypt
Dana-Farber Cancer Institute
Celgene Corporation

Terminated

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck | Basaloid Squamous Cell Carcinoma | Undifferentiated Carcinoma | Adenosquamous Cell Carcinoma
MedImmune LLC

Completed

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Advanced Recurrent Ovarian Tumors

United States
Sun Yat-sen University

Unknown

Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
M.D. Anderson Cancer Center
Amgen

Completed

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

Advanced Cancer | Solid Tumors

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Withdrawn

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

Lung Cancer

United States
Genentech, Inc.

Completed

A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)

Non-small Cell Lung Cancer
AstraZeneca

Completed

Phase II Iressa & Carbo/Gem in NSCLC

Carcinoma, Non-Small-Cell Lung

Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, Hong Kong
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Hepatoblastoma | Fibrolamellar Carcinoma | Childhood Hepatocellular Carcinoma | Childhood Malignant Liver Neoplasm | Hepatocellular Malignant Neoplasm, Not Otherwise Specified

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Vanderbilt-Ingram Cancer Center
Genentech, Inc.

Recruiting

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TESSERACT)

Stage IV Lung Cancer | Extensive Stage Lung Small Cell Carcinoma

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Stage III Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China
Liza Villaruz, MD
Genentech, Inc.

Recruiting

Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Non-small Cell Lung Cancer

United States
Mabscale, LLC

Recruiting

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Russian Federation
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

China
Brian Henick, MD

Recruiting

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

Small-cell Lung Cancer

United States
Akeso

Recruiting

A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

NSCLC

China
Tesaro, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Neoplasms

United States, Canada, Netherlands, Spain, Finland, Belgium, Germany, Israel, Denmark, Sweden, United Kingdom, Poland, Hungary, Norway, Italy, Greece, Czechia, Ukraine, Belarus, Turkey
University of Michigan Rogel Cancer Center
Merck Sharp & Dohme LLC; Clovis Oncology, Inc.

Active, not recruiting

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Head and Neck Cancer

Canada, Spain, Korea, Republic of, United States, Austria, Japan, United Kingdom, Taiwan, Italy, Hungary, Australia, Turkey, Poland, Portugal
Universitaire Ziekenhuizen KU Leuven
European Commission

Completed

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer (EUDARIO)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Germany, Belgium, Italy, Austria, France
Incyte Corporation

Terminated

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma

Spain, France, United States, Italy, Japan, Ireland, Slovakia, Austria, Belgium, Canada, Finland, Germany, Poland, Portugal, Romania, United Kingdom
Professor Fernando Figueira Integral Medicine Institute
Hospital de Câncer de Pernambuco (Recife/PE); AC Camargo Cancer Center (São... and other collaborators

Completed

Short-course HIPEC in Advanced Epithelial Ovarian Cancer

Ovarian Cancer
Massachusetts General Hospital
Bristol-Myers Squibb

Completed

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Lung Cancer

United States
Celgene

Completed

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
United States Department of Defense; Genentech, Inc.

Completed

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer

United States
Hoffmann-La Roche

Completed

BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Ovarian Cancer

Belgium
AstraZeneca

Terminated

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Breast Cancer

Spain, United States
Rigshospitalet, Denmark

Unknown

Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma (SEED)

Stomach Neoplasms | Esophageal Neoplasms

Denmark
Boehringer Ingelheim

Completed

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

Spain
University of California, Davis
Novartis

Terminated

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Yale University
Bayer

Completed

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

Bladder Cancer

United States

Search clinical trials for: carboplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations